With a prevalence of 3-4 % in those >50 years of age, MGUS (Monoclonal Gammopathy of Undetermined Significance) is a common condition. In this presentation, Dr. Charlotte Gran addresses when sFLC should be utilized in MGUS diagnosis, how sFLC assessment is incorporated in risk stratification of MGUS, and how sFLC testing can be incorporated in monitoring of MGUS.
Dr. Charlotte Gran
Center for Hematology and Regenerative Medicine
Department of Medicine
Karolinska Institute
Stockholm, Sweden